Study of an investigational drug for pulmonary sarcoidosis
Treatments studied
Part of Blood & lymphatic, Immune system & allergy, Lungs & breathing clinical trials.
This trial tests an experimental drug to see if it can help people with pulmonary sarcoidosis, which affects the lungs. The drug may work by reducing inflammation, and this study will check its safety and effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a sarcoidosis diagnosis confirmed by biopsy at least 6 months ago.
- Your sarcoidosis must affect your lungs, as shown by a chest X-ray or CT scan.
- You must have active lung sarcoidosis within the last 3 months.
- You cannot have certain other types of sarcoidosis (like heart, eye, or brain) that need treatment that could interfere with the study.
- You cannot be a current smoker or vaper of nicotine, tobacco, or cannabis products (within the last 6 months).
- You must not have a history of active tuberculosis or certain fungal lung infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication, OATD-01, for people with active sarcoidosis in their lungs. It aims to see how safe and effective the drug is and if it can improve symptoms.
This trial tests an experimental drug called XTMAB-16 for people with sarcoidosis in the lungs, which may also affect other parts of the body. The goal is to see if it helps improve breathing and reduce symptoms.
This trial tests a steroid medication called compound betamethasone for people with newly diagnosed pulmonary sarcoidosis (stage I or II). It may help reduce inflammation and improve symptoms compared to standard prednisone treatment.
This trial studies a treatment approach for people with active cardiac sarcoidosis, confirmed by specific heart rhythm/heart function problems and a PET scan. It may help by targeting the active inflammation driving heart conduction problems, rhythm events, or weak heart pumping.
This trial tests a new drug called tulisokibart for people with psoriatic arthritis (PsA), a condition that causes joint pain and skin plaques. It may help if you have not tried certain biologic medications or if they did not work well.
This trial studies whether hydroxychloroquine can control extrapulmonary sarcoidosis (sarcoidosis outside the lungs) using less steroid treatment. It may help people who need systemic therapy for problems such as eyes, skin, bones, joints, nerves, ENT areas, or high calcium levels from sarcoidosis.
Hear when a new Pulmonary Sarcoidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.